Multiple SclerosisNCT06955832
Early Identification of Brain Lesions in Multiple Sclerosis With Phase Sensitive Inversion Recovery MRI
An observational study of Multiple Sclerosis, run by Benha University at 3 sites in Egypt.
Trial summary
The goal of this observational study is to compare the diagnostic accuracy of Phase-Sensitive Inversion Recovery (PSIR) MRI versus conventional T2-weighted (T2W) and Fluid Attenuated Inversion Recovery (FLAIR) sequences in detecting early brain lesions in patients with Multiple Sclerosis (MS). Read more about this study
- Who is it for?
- Ages 15 to 65 years
- Conditions the study is for
- Multiple Sclerosis
- How many people
- 30 participants
- Where
- 3 sitesEgypt
- Study dates
- Jun 2025to Oct 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: This study will enroll participants from three clinical sites in Egypt: * Neurology Department, Banha University Hospitals (Benha, Qalyubia Governorate). * El Mounira MS Unit (Cairo). * Naser Specialized Hospital MS Unit (Cairo). Recruitment Setting: * Outpatient MS clinics at all three sites * Inpatient neurology services at Banha University Hospitals
Who may be able to join
- Age between 15-65 years.
- Both sexes.
- Patients with MS according to McDonald Criterion
Who cannot join
- Age less than 15 years old.
- Patients with stroke or previous intracranial hemorrhage.
- Contraindications to MRI scans.
- MS mimics.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt3 sites, 3 recruiting
- Recruiting
Banha University Hospitals
Banhā, Qalyubia Governorate
Ibrahem Elgendy, 0020133227518, bfomed@gmail.com
- Recruiting
El Mounira Multiple Sclerosis Unit
Cairo
Dr, 0227947205, elmoniratechnicloffice@gmail.com
- Recruiting
Naser Institute MS Unit
Cairo
Dr, 002422014478, nasr.hospital.pur@gmail.com
About this study
Official title: Early Identification of Brain Lesions in Multiple Sclerosis With Phase Sensitive Inversion Recovery MRI: A Cross-sectional Study
The goal of this observational study is to compare the diagnostic accuracy of Phase-Sensitive Inversion Recovery (PSIR) MRI versus conventional T2-weighted (T2W) and Fluid Attenuated Inversion Recovery (FLAIR) sequences in detecting early brain lesions in patients with Multiple Sclerosis (MS). The study will include male and female participants aged 15-65 years diagnosed with MS per the 2017 McDonald criteria.
This study hypothesizes that:
- PSIR MRI will detect a significantly higher number of cortical lesions (intracortical, leukocortical, and juxtacortical) compared to conventional T2W and FLAIR sequences in MS patients (p < 0.05).
- Lesions identified exclusively by PSIR will correlate more strongly with clinical measures (EDSS disability scores and SDMT cognitive performance) than those detected by T2W/FLAIR alone, suggesting PSIR's superior sensitivity to clinically relevant pathology.
Read the detailed description
Introduction Multiple sclerosis (MS) is an immune, demyelinating disease that assaults myelinated axons in the central nervous system (CNS), damaging the myelin and axon to varying degrees. Inflammation, neurodegeneration, and gliosis are hallmarks of MS. Perivascular lymphocytic infiltrate and macrophages destroy the myelin sheaths that pathologically wrap neurons.
In most cases, the condition is relapsing-remitting, with brief bouts of neurologic impairment that resolve entirely. MS pathophysiology is not fully understood but may be connected to hereditary predisposition and a putative non-genetic trigger that results in a sustaining autoimmune disease leading to recurring immunological attacks on CNS.
Several risk factors lead to MS's development, including age, sex, race, heredity, geography, and infections such as herpes simplex, chlamydia, and rabies. MS is likely the result of a complicated interplay between genetics, food, and the environment. MS is primarily caused by an autoimmune attack on the CNS due to hyper immunity. Numerous postulated pathways have been proposed, but the proposed "outside-in" mechanism involves CD4+ proinflammatory T cells.
Cortical demyelinating lesions are defined as focal lesions located entirely inside of the cortical grey matter (pure cortical lesions) or extending partially towards the underlying juxtacortical white matter (leukocortical lesions). These lesions constitute a distinctive characteristic of MS, and their presence aids in identifying patients with an isolated clinical syndrome at higher risk of developing a second clinical episode and, therefore, in predicting the risk of conversion to clinically defined MS. In addition, cortical lesions are not identified in other disease processes which may mimic MS, such as migraine.
Cortical gray matter lesions are a common finding in neuropathlogical studies of multiple sclerosis (MS), and in some studies are more extensive than lesions seen in white matter. However, conventional MRI using T2-weighted, or fluid-attenuated inversion recovery (FLAIR) sequences, reveals few cortical lesions, and is considerably less sensitive to cortical than white matter lesions.
Sensitive method to detect cortical lesions in vivo might assist the diagnosis of MS and provide a new way to monitor the course of MS and its medication by treatment.
Accurate detection and classification of purely intracortical lesions in multiple sclerosis (MS) are important in understanding their role in disease progression and impact on the clinical manifestations of the disease. However, detection of these lesions with conventional MR imaging remains a challenge.
Recent studies have shown that the phase-sensitive inversion recovery (PSIR) sequence, consisting of a heavily T1-weighted sequence with higher signal-to-noise ratio, intensity and gray-white matter contrast has been shown to improve Cortical Lesion detection and inversion recovery combined with phase-sensitive reconstruction, had the highest lesion-to-brain contrast and lesion-limit definition. Therefore, this sequence seemed particularly promising for the detection of cortical lesions.
Subjects and Methods
- Study Design: This study is a cross sectional study.
- Study subjects: The study will be conducted on patients with multiple sclerosis, they will be recruited from neurology department of Banha university hospitals, El Mounira MS unit and Naser specialized hospital MS unit.
- Sample size: Sample size was calculated by Stata Corp. 2021. Stata Statistical Software: Release 17. College Station, TX: Stata Corp LLC., with respect to comparing the ability of detecting cortical lesions with phase sensitive inversion recovery and conventional recovery in MS patients.
Using t test model: difference between two independent means, expected effect size of 0.8; required sample size is 30 MS patients, using α error 5% and a power of 80%.
- Study tools:
Patients with MS will be identified according to:
- Revised McDonald criteria. The "McDonald Criteria" have been extensively assessed and used since 2001 and revised in 2005 and 2017
- Expanded Disability Status Scale (EDSS):
Expanded Disability Status Scale (EDSS) is the most commonly used scale in multiple sclerosis (MS) patients. EDSS is a very effective method of reflecting disability. The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.
- Symbol Digit Modalities Test (SDMT): Is one of the most widely used rapid cognition tests for adults with MS, used to evaluate the cognitive psychometric profile captured by the SDMT to identify whether different cognitive processes independently underlie performance.
- All patients will be subjected to:
- An informed consent will be taken from every patient to confirm approval of participation in the study.
- Complete history taking that include:
- Personal history.
- Past medical and past surgical history.
- Family history.
- Complete physical examination including:
- General examination:
- Local examination of the affected system.
- Neurologic examination
- Investigations
- Imaging:
MRI will be performed at 1.5T using an 8-channel SENSE receive-only head coil with the same protocol for both baseline and follow-up, and patients will be repositioned according to established guidelines.
All images will be analyzed off-line and inspected for presence of major artifacts.
The PSIR images will be obtained for each patient in every session as part of routine MRI sequences, which also will include conventional T2W-TSE and FLAIR., Cortical lesion that will be identified on PSIR will be compared slice by slice with those identified on FLAIRE in order to obtain a corresponding classification.
Two independent neuroradiologists separately will assess all MR images. The number of plaques will be determined in each sequence and compared blindly among sequences.
The plaques will be defined as hyperintense in T2W and FLAIR and as hypointense in PSIR.
The number of plaques will be determined in terms of IC, leukocortical (LC), and juxtacortical (JC) regions. The IC lesions are confined to the GM, while lesions that involved both the cortex and the adjacent WM are identified as LC lesions. Finally, the JC lesions will be WM lesions involving the subcortical U-fibers.
Ethical consideration:
An informed consent will be taken from all subjects prior to the imaging. Ethical considerations according to the ethical committee of Benha University. Statistical analysis All statistical analyses will be performed using Statistical Package for the Social Sciences (SPSS, Version 20.0, Chicago, Illinois). Student t and Mann Whitney tests will be used to compare numerical data. Chi square test will be used to compare categorical data. Spearman's rank correlation coefficients will be used to determine the associations between variables. All p values will be reported as two-sided significance levels and considered statistically significant when p<0.05.
- Conditions
- Multiple Sclerosis
- Keywords
- Multiple Sclerosis, Cortical lesions, MRI, Early diagnosis, McDonald criteria
- Medical subject headings
- Multiple Sclerosis, Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Number and classification of cortical lesions
Total cortical lesion count (sum of intracortical [IC], leukocortical [LC], and juxtacortical [JC] lesions) detected by each MRI sequence (PSIR vs. T2W vs. FLAIR), assessed by two independent neuroradiologists..
Lesion subtype distribution:
- IC lesions (confined to gray matter).
- LC lesions (spanning gray-white matter).
- JC lesions (subcortical U-fiber involvement).
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2025
- Study startJun 2025 (estimated)
- Primary completionJun 2025 (estimated)
- Study completionOct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by Benha UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Benha University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmad Elsayed, Benha University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06955832
- Sponsor's protocol ID
- MD 3-5-2024
- Status last verified
- May 2025
- First submitted
- 25 Apr 2025
- Last updated
- 18 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: It will be only available upon reasonable request from colleagues.
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Identification of Brain Lesions in Multiple Sclerosis With Phase Sensitive Inversion Recovery MRI: A Cross-sectional Study
- ClinicalTrials.gov ID
- NCT06955832
- Acronym / sponsor ID
- MD 3-5-2024
- Conditions
- Multiple Sclerosis
- Keywords
- Multiple Sclerosis, Cortical lesions, MRI, Early diagnosis, McDonald criteria
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Benha UniversityUniversity, hospital or other
- Study start
- Jun 2025 (estimated)
- Primary completion
- Jun 2025 (estimated)
- Study completion
- Oct 2025 (estimated)
- First posted
- 2 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to compare the diagnostic accuracy of Phase-Sensitive Inversion Recovery (PSIR) MRI versus conventional T2-weighted (T2W) and Fluid Attenuated Inversion Recovery (FLAIR) sequences in detecting early brain lesions in patients with Multiple Sclerosis (MS). The study will include male and female participants aged 15-65 years diagnosed with MS per the 2017 McDonald criteria.
This study hypothesizes that:
- PSIR MRI will detect a significantly higher number of cortical lesions (intracortical, leukocortical, and juxtacortical) compared to conventional T2W and FLAIR sequences in MS patients (p < 0.05).
- Lesions identified exclusively by PSIR will correlate more strongly with clinical measures (EDSS disability scores and SDMT cognitive performance) than those detected by T2W/FLAIR alone, suggesting PSIR's superior sensitivity to clinically relevant pathology.
Detailed description
Introduction Multiple sclerosis (MS) is an immune, demyelinating disease that assaults myelinated axons in the central nervous system (CNS), damaging the myelin and axon to varying degrees. Inflammation, neurodegeneration, and gliosis are hallmarks of MS. Perivascular lymphocytic infiltrate and macrophages destroy the myelin sheaths that pathologically wrap neurons.
In most cases, the condition is relapsing-remitting, with brief bouts of neurologic impairment that resolve entirely. MS pathophysiology is not fully understood but may be connected to hereditary predisposition and a putative non-genetic trigger that results in a sustaining autoimmune disease leading to recurring immunological attacks on CNS.
Several risk factors lead to MS's development, including age, sex, race, heredity, geography, and infections such as herpes simplex, chlamydia, and rabies. MS is likely the result of a complicated interplay between genetics, food, and the environment. MS is primarily caused by an autoimmune attack on the CNS due to hyper immunity. Numerous postulated pathways have been proposed, but the proposed "outside-in" mechanism involves CD4+ proinflammatory T cells.
Cortical demyelinating lesions are defined as focal lesions located entirely inside of the cortical grey matter (pure cortical lesions) or extending partially towards the underlying juxtacortical white matter (leukocortical lesions). These lesions constitute a distinctive characteristic of MS, and their presence aids in identifying patients with an isolated clinical syndrome at higher risk of developing a second clinical episode and, therefore, in predicting the risk of conversion to clinically defined MS. In addition, cortical lesions are not identified in other disease processes which may mimic MS, such as migraine.
Cortical gray matter lesions are a common finding in neuropathlogical studies of multiple sclerosis (MS), and in some studies are more extensive than lesions seen in white matter. However, conventional MRI using T2-weighted, or fluid-attenuated inversion recovery (FLAIR) sequences, reveals few cortical lesions, and is considerably less sensitive to cortical than white matter lesions.
Sensitive method to detect cortical lesions in vivo might assist the diagnosis of MS and provide a new way to monitor the course of MS and its medication by treatment.
Accurate detection and classification of purely intracortical lesions in multiple sclerosis (MS) are important in understanding their role in disease progression and impact on the clinical manifestations of the disease. However, detection of these lesions with conventional MR imaging remains a challenge.
Recent studies have shown that the phase-sensitive inversion recovery (PSIR) sequence, consisting of a heavily T1-weighted sequence with higher signal-to-noise ratio, intensity and gray-white matter contrast has been shown to improve Cortical Lesion detection and inversion recovery combined with phase-sensitive reconstruction, had the highest lesion-to-brain contrast and lesion-limit definition. Therefore, this sequence seemed particularly promising for the detection of cortical lesions.
Subjects and Methods
- Study Design: This study is a cross sectional study.
- Study subjects: The study will be conducted on patients with multiple sclerosis, they will be recruited from neurology department of Banha university hospitals, El Mounira MS unit and Naser specialized hospital MS unit.
- Sample size: Sample size was calculated by Stata Corp. 2021. Stata Statistical Software: Release 17. College Station, TX: Stata Corp LLC., with respect to comparing the ability of detecting cortical lesions with phase sensitive inversion recovery and conventional recovery in MS patients.
Using t test model: difference between two independent means, expected effect size of 0.8; required sample size is 30 MS patients, using α error 5% and a power of 80%.
- Study tools:
Patients with MS will be identified according to:
- Revised McDonald criteria. The "McDonald Criteria" have been extensively assessed and used since 2001 and revised in 2005 and 2017
- Expanded Disability Status Scale (EDSS):
Expanded Disability Status Scale (EDSS) is the most commonly used scale in multiple sclerosis (MS) patients. EDSS is a very effective method of reflecting disability. The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability.
- Symbol Digit Modalities Test (SDMT): Is one of the most widely used rapid cognition tests for adults with MS, used to evaluate the cognitive psychometric profile captured by the SDMT to identify whether different cognitive processes independently underlie performance.
- All patients will be subjected to:
- An informed consent will be taken from every patient to confirm approval of participation in the study.
- Complete history taking that include:
- Personal history.
- Past medical and past surgical history.
- Family history.
- Complete physical examination including:
- General examination:
- Local examination of the affected system.
- Neurologic examination
- Investigations
- Imaging:
MRI will be performed at 1.5T using an 8-channel SENSE receive-only head coil with the same protocol for both baseline and follow-up, and patients will be repositioned according to established guidelines.
All images will be analyzed off-line and inspected for presence of major artifacts.
The PSIR images will be obtained for each patient in every session as part of routine MRI sequences, which also will include conventional T2W-TSE and FLAIR., Cortical lesion that will be identified on PSIR will be compared slice by slice with those identified on FLAIRE in order to obtain a corresponding classification.
Two independent neuroradiologists separately will assess all MR images. The number of plaques will be determined in each sequence and compared blindly among sequences.
The plaques will be defined as hyperintense in T2W and FLAIR and as hypointense in PSIR.
The number of plaques will be determined in terms of IC, leukocortical (LC), and juxtacortical (JC) regions. The IC lesions are confined to the GM, while lesions that involved both the cortex and the adjacent WM are identified as LC lesions. Finally, the JC lesions will be WM lesions involving the subcortical U-fibers.
Ethical consideration:
An informed consent will be taken from all subjects prior to the imaging. Ethical considerations according to the ethical committee of Benha University. Statistical analysis All statistical analyses will be performed using Statistical Package for the Social Sciences (SPSS, Version 20.0, Chicago, Illinois). Student t and Mann Whitney tests will be used to compare numerical data. Chi square test will be used to compare categorical data. Spearman's rank correlation coefficients will be used to determine the associations between variables. All p values will be reported as two-sided significance levels and considered statistically significant when p<0.05.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 15 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This study will enroll participants from three clinical sites in Egypt: * Neurology Department, Banha University Hospitals (Benha, Qalyubia Governorate). * El Mounira MS Unit (Cairo). * Naser Specialized Hospital MS Unit (Cairo). Recruitment Setting: * Outpatient MS clinics at all three sites * Inpatient neurology services at Banha University Hospitals
Key inclusion criteria (3 listed)
- Age between 15-65 years.
- Both sexes.
- Patients with MS according to McDonald Criterion
Key exclusion criteria (4 listed)
- Age less than 15 years old.
- Patients with stroke or previous intracranial hemorrhage.
- Contraindications to MRI scans.
- MS mimics.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number and classification of cortical lesions
Time frame: 18 months
Total cortical lesion count (sum of intracortical [IC], leukocortical [LC], and juxtacortical [JC] lesions) detected by each MRI sequence (PSIR vs. T2W vs. FLAIR), assessed by two independent neuroradiologists.. Lesion subtype distribution: * IC lesions (confined to gray matter). * LC lesions (spanning gray-white matter). * JC lesions (subcortical U-fiber involvement).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2025.
- Individual participant dataSharing planned: Undecided. It will be only available upon reasonable request from colleagues.
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis, run by Benha University at 3 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number and classification of cortical lesions (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2025.